Drugs / IBI 360
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05043298 | Oct 2021 → Aug 2023 | neoplastic disease or syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI 360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05043298 ↗ |
| Route | Intravenous | “IBI 360 dose level of escalation IV Q3W Day 1” NCT05043298 ↗ |